Email Updates

Search form

You are here

2 AUGUST 2019 VOLUME 20 ISSUE 29

Media Coverage

  • Specialists in adolescent and teenage health have called upon the government to embed Pre-exposure prophylaxis (PrEP) services in existing Sexual and Reproductive Health Rights (SRHR) services for Adolescent Girls and Young Women (AGYW).

    August 2, 2019
    New Vision
  • In a large cohort of people taking pre-exposure prophylaxis (PrEP) in San Francisco, the rate at which they contracted HIV was nearly eight times higher during the period after some stopped taking PrEP compared with the rate seen while the population was on Truvada (tenofovir disoproxil fumarate/emtricitabine) for HIV prevention.

    August 1, 2019
    POZ
  • Bright and proper in a vivid print dress, Fauza has been offered the only lucky break she has ever had – and seems determined to make the most of it. If it works out, her circumstances and those of her baby daughter will be lifted, perhaps transformed. Getting it right could make the difference between a lifespan measured in decades rather than years for mum and daughter.

    July 31, 2019
    General
    Telegraph
  • Funding for HIV prevention research and development is slowing down, according to a new report by the Resource Tracking for HIV Prevention Research and Development Working Group, a collaboration between global HIV organisations – AVAC, IAVI and UNAIDS.

    July 31, 2019
    General
    Independent
  • The rates of HIV infection in Illinois are decreasing among adults, but are climbing among people ages 13 to 24, especially youth of color. So, advocates want to encourage young people to use a preventative medication.

    July 31, 2019
    NPR
  • Jacqueline Wambui, a resident of Nairobi, Kenyan capital, has been living positively with HIV for several years now. The member of National Empowerment Network of People Living with HIV and AIDS in Kenya (NEPHAK) has become an AIDS activist, with her work involving championing for the rights of HIV patients.

    July 31, 2019
    Xinhua
  • An experimental HIV vaccine that targets more strains of the virus than any other developed so far will start a late-stage clinical trial later this year. The ‘mosaic’ vaccine, which incorporates genetic material from HIV strains from around the world, also seems to have the longest-lasting effects of any others tested in people.

    July 31, 2019
    Nature
  • Zimbabwe recorded a decrease in new HIV infections from 44,000 to 38,000 cases annually, a development which the UNAIDS 2019 report projects may lead to a decline in prevalence.

    July 31, 2019
    General
    The Herald
  • A few years ago, researchers at Harvard and Kaiser Permanente Northern California had an inspired idea: Perhaps they could use the wealth of personal data in electronic health records to identify patients at high risk of getting infected with HIV.

    July 30, 2019
    New York Times
  • Advances in HIV treatment options and studies on HIV prevention for women and girls were among the highlights yesterday at the 10th International AIDS Society Conference on HIV Science (IAS 2019). On the third and final day of the conference, Carl Dieffenbach, Ph.D., Director of the Division of AIDS at NIH's National Institute of Allergy and Infectious Diseases (NIAID), and his colleague Anne Rancourt joined us for a Facebook Live session to discuss those studies, reflect on key meeting takeaways, and look ahead to research developments on the horizon.

    July 30, 2019
    The Body
  • A broad swath of Southerners support HIV prevention policies such as expanding Medicaid, requiring insurance companies to cover pre-exposure prophylaxis (PrEP) and teaching medically accurate, comprehensive sex education in public schools. Those are the findings of a public opinion poll in seven Southern states. However, the poll also found that many respondents were not knowledgeable about the science behind HIV prevention.

    July 30, 2019
    POZ
  • Health authorities have uncovered an alarming surge in resistance to crucial HIV drugs. Surveys by the World Health Organization (WHO) reveal that, in the past 4 years, 12 countries in Africa, Asia and the Americas have surpassed acceptable levels of drug resistance against two drugs that constitute the backbone of HIV treatment: efavirenz and nevirapine.

    July 30, 2019
    Nature
  • The microbiome, which refers to the vast collection of microbes living in and on our bodies, has been previously associated with increased risk of HIV infection. However, it has not been studied extensively in the context of HIV prevention technologies, such as anti-retroviral based pre-exposure prophylaxis and vaccines. The new research collaborative will evaluate how differences in the microbiome of the genital tract and gut affect host inflammation, the effectiveness of these drugs and immune responses stimulated by HIV vaccines.

    July 29, 2019
    General
    Imperial College London
  • More than 5,000 people from 140 counties gathered in Mexico City for the opening of the 10th IAS Conference on HIV Science (IAS 2019), where global experts called for urgent action to address the health needs of millions of people affected by humanitarian crises.

    July 28, 2019
    General
    The Daily Star
  • Dolutegravir (DTG), a drug previously feared to cause deformities in unborn children, is now the preferred HIV treatment option, even among women of reproductive age.

    July 28, 2019
    The East African
  • The tools needed to end the worldwide AIDS epidemic are either in the hands of clinicians, governments, or patients, or can be implemented by using government and social willpower, researchers said here at the International AIDS Society Conference on HIV Science.

    July 26, 2019
    General
    MedPage Today
  • Islatravir, also known as MK-8591, was effective against HIV infection when included as part of a three-drug antiretroviral therapy (ART) combination, a researcher said here.

    July 25, 2019
    MedPage Today
  • Stigma remains a significant barrier to the uptake and continued use of pre-exposure prophylaxis (PrEP) by key populations in Kenya, according to qualitative research presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City by Dr Daniel Were of the Jilinde Project and Jhpiego.

    July 24, 2019
    aidsmap
  • “What HIV has pointed out is that building it does not make them come,” Ambassador Dr. Deborah Birx noted at an opening night press event that highlighted persisting gaps in HIV testing, treatment, prevention access across the globe. When services don’t reach clients and communities, she said, people offering them have to ask why they missed their target. She offered a hint: “The client and the community need to be at the center.”

    July 23, 2019
    General
    Science Speaks
  • Imagine if women could take one pill every day and be protected from unintended pregnancy and HIV? And what if this pill was available within several years? We believe the fastest route to a contraceptive MPT is to combine two products that are already on the market into a single pill. A dual-purpose pill has the potential to play an important role in helping women protect themselves against both unintended pregnancy and HIV infection.

    July 22, 2019
    IMPT Blog

Published Research

Announcements